US SB481 | 2015-2016 | 114th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on February 12 2015 - 25% progression, died in chamber
Action: 2015-10-01 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 245.
Text: Latest bill text (Introduced) [PDF]

Summary

Improving Regulatory Transparency for New Medical Therapies Act (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to delay the effective date of approval of a drug, biological product, or animal drug for which the Food and Drug Administration (FDA) recommends controls under the Controlled Substances Act until the Department of Justice (DOJ) issues a final interim rule for the drug. This delay also applies to conditional approval and indexing of animal drugs. This bill amends the Controlled Substances Act to require the DOJ to issue a final interim rule for a drug product recommended for controls by the FDA not later than 90 days after DOJ receives a recommendation for controls or the FDA approves the drug. The final interim rule is effective immediately. For purposes of submitting an application to extend a patent, a drug product recommended for controls is considered to be approved and have permission for commercial marketing and use on the date of FDA approval or the date an interim final rule is issued, whichever is later. (Sec. 3) Timelines are established for DOJ to either register an applicant to manufacture a controlled substance for a clinical trial or serve an order to show cause upon the applicant. (Sec. 4) This bill amends the Controlled Substances Import and Export Act to allow exported controlled substances to be re-exported within the European Economic Area.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Improving Regulatory Transparency for New Medical Therapies Act

Sponsors


History

DateChamberAction
2015-10-01SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 245.
2015-10-01SenateCommittee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
2015-09-30SenateCommittee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
2015-02-12SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Same As/Similar To

HB639 (Related) 2015-11-25 - Became Public Law No: 114-89. (TXT | PDF)

Subjects


US Congress State Sources


Bill Comments

feedback